Is There Pet Insurance With No Waiting Period? – MarketWatch

In this article: Purpose of a Waiting Period | Pet Insurance With No Waiting Period | Typical Waiting Period | Top Companies With Short Waiting Periods | FAQs

When you buy pet insurance, youll need to wait before coverage begins. Accidents, injuries, and symptoms of illnesses or conditions during this waiting period are considered preexisting and arent covered under your policys terms. If you want this waiting period to be as short as possible, these are the best pet insurance companies for you.

Pet insurance is intended to cover health conditions that may happen in the future, not ones that have already occurred. Pet insurance companies would lose money if they insured pets with known expensive health problems, which is why none cover preexisting conditions.

Since most providers dont require your pet to get a health exam before enrolling in coverage, waiting periods are meant to prevent you from noticing symptoms or injuries, quickly signing up for insurance, and then immediately receiving veterinary care paid for by the company. Essentially, the waiting period allows pet owners to enroll in a policy quickly while keeping people from gaming the system.

Nearly all pet insurance plans have a waiting period, though some may have shorter periods for accident-only coverage. A few emergency-only policies dont fit the standard insurance mold and have no waiting periods, but the coverage is often minimal.

The typical waiting period is 14 days, particularly for illness coverage. Some pet insurance providers have a waiting period of only a few days for accident coverage. Hereditary conditions such as hip dysplasia typically have much longer waiting periods up to a year. If your pet develops symptoms of a health problem within that time frame, expenses for that health problem will not be covered whether a vet provides treatment or not.

Here are the pet insurance companies with the shortest waiting periods.

Lemonade offers comprehensive coverage and multiple add-ons at more affordable rates than many providers on this list. It also has a very short waiting period for accident coverage of only 48 hours.

+ Waiting period for accidents is only 48 hours

+ Lower monthly premiums than many competitors

+ Add-on option for preventive care

Requires a recent vet exam to qualify

No coverage for pets older than 14

Lemonade offers one pet insurance plan covering costs related to accidents and illnesses, such as diagnostic tests, hospitalizations, surgery, cancer treatments, broken bones or sprains, prescription medications and more. You can add coverage for wellness exams, vaccines, bloodwork and physical therapy treatments.

To learn more: Lemonade Pet Insurance review

Get your quote: Fill out Lemonades online quote form

A newcomer to the pet insurance industry, Spot offers highly customizable plans, including annual limits from $2,500 to unlimited. Although its 14-day waiting period is average, it applies to knee and ligament conditions, which often have much longer waiting periods.

+ Option for unlimited annual coverage

+ 14-day waiting period for knee and ligament coverage

+ 10% multi-pet discount

Accident coverage doesnt start for 14 days

No customer service on weekends

Spot offers two plans: one for accident-only coverage and one for accidents and illnesses. It also has two wellness add-ons for preventive care.

To learn more: Spot Pet Insurance review

Get your quote: Fill out Spots online quote form

Trupanion offers unlimited coverage caps and a range of deductibles from $0 to $1,000 to customize your plan. Its five-day waiting period for accidents and injuries is shorter than many providers. Its 30-day waiting period for illnesses and other conditions is longer than average, but it applies to joint problems such as cruciate ligament and hip dysplasia.

+ Covers hereditary and congenital conditions

+ Pays veterinarian directly

+ No payout limits

30-day waiting period for illnesses

No option for wellness or preventive care

Trupanion offers one comprehensive accident-and-illness plan. It also covers conditions that can occur outside of an accident or illness, such as congenital and hereditary conditions and other undiagnosed issues. It includes add-on coverage for several unique items, such as alternative treatments, advertising for lost pets, boarding fees and breeding costs.

To learn more: Trupanion review

Get your quote: Fill out Trupanions online quote form

Fetch Pet Insurance, formerly PetPlan, only offers one accident-and-illness plan. However, the plan includes coverage for things many providers dont cover, such as holistic care, stem-cell therapy and treatment related to behavioral problems such as separation anxiety or aggression.

+ Offers coverage for some nonmedical expenses

+ Covers alternative and complementary treatments

+ Healthy Pet Credit discount for 12 years without filing a claim

No multi-pet discount

No add-on for wellness coverage

Fetch offers one accident-and-illness plan. It doesnt have any add-on options.

To learn more: Fetch by The Dodo Pet Insurance review

Get your quote: Fill out Fetchs online quote form

Embrace provides pet parents with multiple opportunities to save, including a 10% discount for each additional pet policy you purchase, a 5% military discount and a 10% discount for employees of companies that offer Embrace pet insurance. It also provides a Healthy Pet Deductible benefit that credits $50 toward your co-payment each year you dont file a claim.

Although Embrace has a six-month waiting period for orthopedic conditions, you can apply for the Orthopedic Exam and Waiver to reduce this time frame. The waiting period for accident coverage is only two days.

+ Option to add coverage for routine care such as vaccinations

+ Diminishing deductible for years without filing claims

+ Coverage for working dogs (racing, guarding, etc.)

Low dollar limit for wellness coverage

No coverage for prescription food or supplements

Embrace offers one accident-and-illness plan plus an add-on for preventive care.

Note: The Wellness Rewards plan is not available in Rhode Island.

To learn more: Embrace Pet Insurance review

Get your quote: Fill out Embraces online quote form

Most companies max out their reimbursement rate at 90%, but Figo offers up to 100% reimbursement for claims. Its one-day waiting period for accidents and injuries is also the lowest in the industry. You can apply for a waiver to get around the six-month waiting period for orthopedic conditions.

+ Offers 100% reimbursement option

+ Shortest waiting period for accidents

+ Extra Care Pack covers end-of-life costs, boarding, theft and more

Coverage for exam fees requires add-on

High deductibles for older pets

Figo offers one accident-and-illness plan with three tiers of coverage and annual limits. It also has a range of add-ons for items such as preventive care and liability coverage for damages or injuries your pet causes.

Get your quote: Fill out Figos online quote form

Pets Best stands out for its coverage of older pets. Unlike some competitors, it has no age limit for coverage, meaning you can enroll your pet anytime. It also offers coverage for items more likely to be required by aging pets, such as prescribed prosthetic devices and wheelchairs.

Pets Best has an average waiting period, but if you add one of the two routine care plans, you can use your pet insurance policy for wellness care immediately.

+ Highly customizable plans

+ Vet Direct Pay reimburses veterinarians directly

+ Covers prosthetic devices and wheelchairs

Exclusions for parasites, behavioral treatment and prescription food

Illness coverage not offered to pets with severe chronic conditions

Pets Best offers an accident-only plan, three levels of accident-and-illness coverage and two routine care add-ons.

Unfortunately, all pet insurance providers have waiting periods. The standard waiting period is 14 to 15 days for accidents and illnesses. Many of the companies listed above offer shorter-than-average waiting periods for accidents or orthopedic conditions. Although the waiting period shouldnt be the only factor you take into account, it may be important to consider while shopping for pet insurance.

Our review of pet insurance companies is based on in-depth industry research that includes reading hundreds of customer reviews, simulating the quote and purchasing process, speaking to representatives on the phone to assess the customer service experience and surveying 1,000 dog and cat owners nationwide to determine the most important elements of pet insurance coverage. We have scored each provider on a 100-point scale based on those elements.

Here are more details about each factor and how theyre weighted:

We use our rating system to compare and contrast each company against key factors to help us determine the best pet insurance companies in the industry. Additionally, we keep our research up to date and revisit our reviews on a regular basis.

More here:
Is There Pet Insurance With No Waiting Period? - MarketWatch

CAR-T Cell Therapy Completely Cures Autoimmune Disease in Several Patients – Inside Precision Medicine

Researchers at Friedrich-Alexander-University Erlangen-Nrnberg (FAU), in Germany have successfully cured several patients suffering from severe systemic lupus erythematosus (SLE) using genetically modified immune cells known as CAR-T cells.

CAR T cells are immune cells taken from an individual patient and genetically engineered to express proteins known as CARchimeric antigen receptorson their surface in order to bind specific proteins on the surface of target cells and eliminate them. CAR-T cells are a form of personalized therapy and already approved as a treatment for several cancers in the U.S.

In the first study of its kind, published in Nature Medicine, researchers at FAU have now modified CAR T cells to attack immune cells known as B cells which produce harmful antibodies against the bodys own cells in autoimmune diseases such as SLE, with astonishing results.

We have been able to help six young patients who were suffering from a life-threatening form of SLE and cure them of the disease completely by treating them with CAR-T cells, said Prof. Georg Schett, PhD, director of the Department of Medicine at FAU and senior author of the study in a press statement.

SLE is a severe form of autoimmune disease in which immune cells form antibodies that attack the bodys own DNA leading to the inflammation of internal organs. Patients suffering from the disease are often dependent on immunosuppressive drugs in order to manage the symptoms such as extreme fatigue and joint pain. For their trial, the researchers recruited treatment-resistant SLE patients with all trial participants showing damage in multiple organs, such as the kidneys, heart and lungs.

What is special about this is that a single infusion of CAR-T cells brought down the inflammation and autoimmune response like a house of cards, and the patients were able to stop all therapy including corticosteroids, said Schett.

The researchers compared the treatment to pressing a reset button in the immune system. According to Prof. Dimitros Mougiakakos, PhD, director of the department of hematology, oncology and stem cell transplantation at the University of Magdeburg and co-author of the study, 100 days after CAR T cell therapy the B cells returned but the disease continued to stay away.

When the immune system of treated patients is examined, it is surprising that the newly-emerged B cells are naive, similar to a baby. We can therefore be confident is saying that a reset button really has been pressed here, said Prof. Gerhard Krnke, PhD, professor of translational immunology at FAU and co-author of the study in a press statement.

However, due to not only diseased but all B-cells being eliminated, CAR T cell therapy carries a risk of causing cytokine release syndrome in which T cells produce pro-inflammatory molecules known as cytokines into the bloodstream, thus making the therapy potentially unsuitable for patients with only mild symptoms.

To ensure the CAR T cell therapy didnt harm the immune system of the patients in the trial, the researchers tested their antibody amounts in response to several vaccines such as measles, mumps and hepatitis B before and after the treatment. Overall, they didnt find a significant difference in antibody titers concluding that the CAR T cells mainly destroy the disease-causing B-cells producing autoantibodies.

As a next step the scientists at FAU are planning to conduct a larger basket clinical trial, where patients with different kinds of severe autoimmune diseases will receive CAR T cell therapy.

Continued here:
CAR-T Cell Therapy Completely Cures Autoimmune Disease in Several Patients - Inside Precision Medicine

Biopreservation Market worth USD 9.5 Billion by 2030, says Global Market Insights Inc. – GlobeNewswire

Selbyville, Delaware, Sept. 26, 2022 (GLOBE NEWSWIRE) --

The biopreservation market value is anticipated to cross USD 9.5 billion in revenue by 2030, according to a new research report by Global Market Insights Inc.

Increasing demand for regeneration medicines due to rising occurrences of lifestyle diseases will drive the industry trends. Growing need for effective healthcare systems, along with prominent healthcare expenditure, will increase the demand for biopreservatives. The soaring cases of chronic diseases among the elderly population have encouraged government agencies to spend massively on healthcare, pushing gene banks, bio banks and hospitals to focus on biopreservation.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/762

Wide applicability in research laboratories to push the industry landscape

Biopreservation market from equipment segment was valued at over USD 3.5 billion in 2021, due to the growing demand for biopreservation equipment to preserve blood, vaccines, and more, in hospitals and laboratories. The equipment includes freezers, refrigerators, consumables, and liquid nitrogen and are widely utilized in DNA, stem cell, plasma, and tissue research sectors.

CD34+ cell provider segment to foster market expansion

The CD34+ segment was worth more than USD 810 million in 2021. This is attributed to the prevalent use of cell surface marker CD34+ for the diagnosis of hematopoietic stem cells that can differentiate into multiple lineages. Blood from newborns umbilical cords is a crucial source of these cells. Notable advancements in stem cell research will stimulate product penetration.

Browse key industry insights spread across 260 pages with 413 market data tables & 13 figures & charts from the report, Biopreservation Market Analysis By Product (Equipment {Freezers, Refrigerators, Consumables [Vials, Straws, Microtiter, Bags], Liquid Nitrogen}, Media {Pre-formulated, Home-brew}, Laboratory Information Management System [LIMS]), By Application (Regenerative Medicine {Cell Therapy, Gene Therapy}, Biobanking {Human Eggs, Human Sperm, Veterinary IVF}, Drug Discovery), By Cell Provider (CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells), Industry Analysis Report, Regional Outlook Growth Potential, Competitive Market Share & Forecast, 2022 2030 in detail along with the table of contents:

https://www.gminsights.com/industry-analysis/biopreservation-market

High demand for advanced storage facility to boost industry size

Biopreservation market from regenerative medicine segment accounted USD 1 billion in 2021. owing tothe rising demand for advancedbio storage facilities. Intensifying demand for regenerative therapies that require regenerative medicines will propel the demand for effective bio-storage procedures. For instance, in September 2022, CIRM provided around $2.7 million to UCI to establish a regenerative medicine training program to spread awareness regarding its benefits.

North America to emerge as a prominent regional market due to surging incidences of chronic diseases

North America biopreservation market held a substantial industry share of more than 45% in 2021 and is slated to depict significant growth over the assessment timeframe. Exponential demand for diagnosis of chronic diseases may be a key factor pushing regional market revenue. In addition, government guidelines supporting ethical usage of biological samples and the development of novel drugs & therapies in the healthcare space will foster the North America industry outlook.

Effective expansion plans to remain a vital development strategy for industry players

The competitive landscape of the biopreservation market is inclusive of Arctiko A/S, Thermo Fisher Scientific Inc, PHC Holdings Corporation, Cryport, Inc, Eppendorf AG, Helmer Scientific, VWR International (Avantor, Inc.), Biolife Solutions, Azenta, and Merck KGaA. These companies primarily focus on research and development and enter into strategic mergers and collaborations to proliferate their market position.

Request for customization of this research report @ https://www.gminsights.com/roc/762

About Global Market Insights

Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.

Go here to see the original:
Biopreservation Market worth USD 9.5 Billion by 2030, says Global Market Insights Inc. - GlobeNewswire

A glimpse into Indian consumers expectations for cosmetic treatments and consumption insights – The Financial Express

By Dr Chytra V Anand

The fascination with beauty and skincare in India has grown leaps and bounds in recent times, and understandably so, given that the culture of beauty is deeply rooted in the country. The days when beauty was an aspect of social class and the cosmetic treatments and products you access gave away your economic status are long gone, as are the days when cosmetic treatments were considered a girl thing. With cosmetic treatments becoming more accessible and sought-after, the Indian skincare and derma cosmetics market generated an estimated revenue of a whopping USD 188.2 million in 2021. The same is projected to grow at a CAGR of 10.2% between 2021 and 2030.

Today, with changing lifestyles, demographic growth, cutting-edge technology, and improving economic and social conditions thanks to rising per capita and disposable income, India is quickly heading towards becoming a leader in the global cosmetics industry. But for a bit of self-introspection, what are Indian consumers looking for when it comes to cosmetic treatments? What does their consumption tell industry players?

Alzheimers is the most common form of dementia

Nutraceuticals: A healthy alternative to pharmaceutical drugs

We wish to leverage technology to make Yoga accessible to everybody globally: Karan Talreja, RESET Tech

Should you drink water before or after brushing your teeth? Read on to find out

Body hair removal has become one of the most popular cosmetic procedures done across the world today. But compared to shaving, waxing, or using an epilator or a trimmer, laser hair removal is a more permanent hair removal method that has gained immense traction of late. Especially in urban India, laser hair removal has quickly gained popularity, with mothers even bringing their 16-year-olds for Laser hair removal.

In 2021, the global laser hair removal market was valued atUSD 798.6 million, with an estimated CAGR of 18.4% from 2022 to 2030. Given that laser hair removal is a one-time procedure, although one has to sit through multiple sessions, the results, when done by a reliable cosmetic professional, are impressive. The Asia Pacific is projected to be the fastest-growing segment for laser hair removal, especially in countries like India and China.

A cosmetic procedure where a chemical solution is applied to your skin to remove the top layers, Chemical Peels ensure that the skin becomes smoother and clearer, making it radiant. On the other hand, a Medical Clean-up, in the simplest terms, is the procedure of cleaning your skin, ridding impurities like blackheads and white head spots to clear clogged pores. Besides, Medical Clean-ups are also beneficial for people struggling with acne scars, making it a popular procedure that an increasing number of people are choosing. For Chemical Peels, the market size is expected to touch USD 68.81 million between 2021 to 2025, making their popularity surge.

As we grow older, our skin begins to age too, and wrinkles and fine lines begin to appear on our face. Cosmetic procedures like Hydra Facials and skin maintenance with Laser Photofacials are a weekly must-do for 30-45-year-olds to ensure their skin is supple and glowing. Apart from this, the perception of Indian consumers when it comes to cosmetic treatments like Botox and Fillers has begun to change. These are no longer viewed as taboo as people now realise that they give your skin a lift.

Such treatments are also no longer only available for a certain section of society, like the wealthy. Botox and Fillers are now available to everyone, and consumers are looking at them from a skin maintenance standpoint rather than as a luxury, unnecessary treatment. Annually, the Botox segment is registering 20-25% growth in the country proof of evolving consumer preferences and the rising popularity of such treatments. Besides these, derma cosmetics and medical skin care have also gained a fair amount of traction, with skincare aficionados looking for effective and efficient skin care procedures that are non-surgical.

Alongside our skincare, taking care of our mane is equally important. For people struggling with hair fall, flaky and dry scalp, and other issues that affect your hair, stem cell therapy is the answer. Often done annually, stem cell therapy helps rejuvenate your hair cells to retain hair and repair damage. And with the global hair restoration market standing at over USD 4.2 billion in 2020, we can safely say its here to stay.

With consumerism changing face gradually and Indian consumers gaining access to world-class cosmetic treatments that are non-surgical, which still trump surgical procedures, the future of the Indian cosmetic treatments market shines bright. As long as the procedures are done by qualified and experienced professionals and are reliable and effective, the demand for such cosmetic procedures will continue to grow.

(The author isfounder ofKosmoderma Healthcare Pvt. Ltd.Views expressed are personal and do not reflect the official position or policy of the FinancialExpress.com.)

See the original post here:
A glimpse into Indian consumers expectations for cosmetic treatments and consumption insights - The Financial Express

WHIM Syndrome: Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market – Digital Journal

WHIM Syndrome Market I

DelveInsights WHIM Syndrome Market Insights, Epidemiology, and Market Forecast2032 report delivers an in-depth understanding of the WHIM Syndrome, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

DelveInsights WHIM Syndrome Market Insights, Epidemiology, and Market Forecast2032 report delivers an in-depth understanding of the WHIM Syndrome, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The WHIM Syndrome market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted WHIM Syndrome symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current WHIM Syndrome symptoms treatment practice/algorithm and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Some of the key facts of the WHIM Syndrome Market Report:

Key benefits of the Whim Syndrome Market report:

With only symptomatic and no curative therapies approved in any markets, there exists a major unmet need for therapies that target the underlying cause of the disease to address the symptoms of WHIM Syndrome, to treat the patients effectively.

To counter unmet market needs and provide better treatment choices for WHIM Syndrome, several market players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the study period, likely to drive market growth during the study period.The major market players in WHIM Syndrome therapeutic market include X4 Pharmaceuticals, among others.

Got queries? Click here to know more about the Whim Syndrome Landscape

Whim Syndrome Market Overview

WHIM syndrome is a primary immunodeficiency disorder, one of a group of disorders characterized by irregularities in the cell development and/or cell maturation process of the immune system. The term WHIM is an acronym for the main signs of the syndrome: warts, hypogammaglobulinemia, infections, and myelokathexis. It is an autosomal-dominant combined immunodeficiency disease caused by mutations in the receptor CXCR4, resulting in increased bone marrow retention and severe reduction in circulating neutrophils.

WHIM Syndrome Diagnosis and Treatment

The treatment for WHIM syndrome can be mainly categorized into two categories: curative treatment and symptomatic treatment. Hematopoietic stem cell transplantation (allogenic) is the only available curative treatment for WHIM syndrome, whereas the symptomatic treatment involves the exogenous administration of immunoglobulins (IV/subcutaneous), G-CSF, and CXCR4 antagonists. Few major unmet needs in the market include no approved therapies, challenges in current symptomatic treatment options, challenges in hematopoietic stem cell transplantation (HSCT), lack of universal diagnostic criteria, and complicated diagnosis of the condition.

Whim Syndrome Market Epidemiological Insight

Whim Syndrome Market Epidemiological Segmentation

Whim Syndrome Market Outlook

The reports WHIM Syndrome market outlook helps to better understand the historic, current, and forecasted WHIM Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of WHIM Syndrome market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

According to DelveInsight, the WHIM Syndrome market in 7MM is expected to grow steadily during the study period 20192032.

The current management options for WHIM syndrome can be mainly categorized into two categories: curative treatment and symptomatic treatment. Hematopoietic stem cell transplantation (allogenic) is the only available curative treatment for WHIM syndrome, whereas the symptomatic treatment involves administration of granulocyte-colony stimulating factor (G-CSF), exogenous administration of immunoglobulins (IV/subcutaneous), G-CSF, and CXCR4 antagonists.

The major market players in WHIM Syndrome therapeutic market are Amgen, Sandoz (Novartis), Pfizer, Takeda, and X4 Pharmaceuticals, among others.

Learn more by requesting for sample @WHIM Syndrome Market Landscape

WHIM Syndrome Key Companies

WHIM Syndrome Therapies

Table of Contents

Click here to read more about WHIM Syndrome Market

Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Adya Kaul Email: Send Email Phone: 9193216187 Address:304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website: https://www.delveinsight.com/

Originally posted here:
WHIM Syndrome: Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market - Digital Journal

20220927 Seven New CSL Global Research Acceleration Initiative Awardees Announced – CSL Limited

MELBOURNE, AUSTRALIA - 27 September 2022:Seven medical researchers have been awarded a CSL Research Acceleration Initiative (RAI) partnership, including up to an AU$500,000 investment in each program over two years, to fast-track the discovery of innovative biotherapies to address unmet medical needs.

The CSL Research Acceleration Initiative establishes partnerships between CSL and global research organisations to accelerate commercialisation of promising discovery programs. In addition to creating long-term mutual partnerships to further innovation, the initiative includes funding as well as access to CSL R&D experts.

The seven Global RAI awardees, selected via the 2021 call for proposals, include researchers from: The University of Queensland, University of Newcastle and ANZAC Research Institute in Australia; University of Pennsylvania in the US; Justus Liebig University Giessen and University Hospital of Ludwig Maximilian University of Munich in Germany; and University of Basel in Switzerland.

Dr Marthe DOmbrain, CSLs Head of Global Research Innovation said, Through our Global Research Acceleration Initiative, we are able to tap into and support research innovation happening in all corners of the world. We are looking forward to collaborating with our new partners to support the development of their exciting discoveries.

These Global RAI awardees research addresses important unmet medical needs across CSLs therapeutic areas, including immunology, transplant, respiratory, hematology, and cardiovascular and metabolic disease.

The investigators and technologies selected in the 2021 call for proposals include:

Professor Allison Pettit, The University of Queensland, Australia Prof. Pettit is exploring a new therapeutic approach to improve homing and engraftment of hematopoietic stem cell transplants. Prof Pettits program aims to reduce graft failure and risk of infection, thus significantly improving outcomes for patients.

Dr Kirsten Coupland, University of Newcastle, Australia Dr. Coupland is researching novel therapeutic targets for acute ischemic stroke, one of the leading causes of mortality worldwide. Dr Couplands work focuses on understanding how the composition of cerebrospinal fluid changes following a stroke.

Associate Professor Georgina Clark, ANZAC Research Institute, Australia A/Prof. Clark is developing a new treatment that could reduce the requirement for chemotherapy during a hematopoietic stem cell transplant, thus improving safety and enabling more patients to benefit from this potentially curative approach.

Professor Daniel Rader, University of Pennsylvania, United States of America Prof. Rader is developing a novel therapy for reducing triglycerides (a type of fat) in the blood. Patients with very high triglycerides can develop severe and sometimes life-threatening pancreatitis.

Professor Elie El Agha, Justus Liebig University Giessen, Germany Prof. El Agha's research program is focused on novel cellular and molecular pathways implicated in the pathobiology of idiopathic pulmonary fibrosis; a progressive lung disease that currently has no cure.

Professor Arthur Liesz, University Hospital of Ludwig Maximilian University of Munich, Germany Prof. Liesz investigates the interplay between our immune system and the brain. Understanding the role the immune system plays in exacerbating cardiovascular events, including in acute ischemic stroke and myocardial infarction, may identify novel treatment approaches.

Professor Daniel Ricklin, University of Basel, Switzerland Prof. Ricklin is developing novel therapeutic candidates to target inflammation. This approach could be applied to many serious diseases including immune complex mediated autoimmune disorders.

Dr DOmbrain said that the RAI recipients research addresses important unmet medical needs where there is often limited or no existing treatment options available for patients. We want to look back in years to come and see projects accelerated via our Research Acceleration Initiative making a difference to the lives of patients across the globe.

We look forward to helping transform these ideas into what we hope will ultimately be ground-breaking therapies to improve the lives of people living with these conditions, said Dr DOmbrain.

Providing life-saving medicines to patients in over 100 countries, CSL is driven by its promise to advance and deliver innovations that address rare and serious diseases as well as protect public health. Each year, CSLs Global Research Acceleration Initiative works to identify promising research programs around the world which will benefit most from fast-tracked industry collaboration and support. More than 25 new partnerships have been established via the Research Acceleration Initiative since 2019.

For more information about the CSL Research Acceleration Initiative, please visit: http://www.csl.com/csl-rai

Media ContactKim ODonohue M: +61 449 884 603 E: kim.odonohue@csl.com.au

About CSL CSL Limited (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor provides lifesaving products to patients in more than 100 countries and employs 30,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSL. For more information visit csl.com.

Continued here:
20220927 Seven New CSL Global Research Acceleration Initiative Awardees Announced - CSL Limited

Cell-free Protein Expression Market to be Worth $475.1 Million by 2030 – Grand View Research, Inc. – Yahoo Finance

SAN FRANCISCO, Sept. 26, 2022 /PRNewswire/ -- The global cell-free protein expression market share is expected to reach USD 475.1 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.48% from 2022 to 2030. Growing demand for novel biologic products for the treatment of severe chronic diseases such as, cancer, multiple sclerosis, and anemia is a major factor contributing to the market growth. For instance, as reported by the world health organization (WHO) in 2020, there were 10 million deaths or about 1 in 6 deaths due to cancer making it to be one of the major causes of death worldwide. Such rising cancer incidences are increasing the adoption of protein biologics as an alternative treatment option due to their target-specific treatment with fewer side effects compared to other treatments which is positively impacting the market growth.

Grand View Research, Inc., Logo

Funding in genomic sciences and precision medicine R&D is aiding the market growth. For instance, in May 2022, the Medical College of Wisconsin's Center for Genomic Sciences and Precision Medicine received USD 10 million funding for exploring genomic applications for the treatment of various rare and undiagnosed diseases. Moreover, investments by government initiatives are advancing and expanding the R&D activities of proteomics. For instance, in August 2020, the National Institutes of Health granted a $10.6 Million Federal Grant to the University of Arkansas for Medical Sciences to expand its proteomic resources. Similarly, in June 2022 British Columbia government invested and is managing large-scale genomics and proteomics research projects based on health, forestry, and agriculture among others. Thus, such funding initiatives are expected to boost the adoption of the proteomics and genomics in R&D and fuel the market growth during the forecast period.

Key Industry Insights & Findings from the report:

By product, the expression systems segment held the largest share of the cell-free protein expression market. E. coli lysates is one of the most preferred lysates commercially due to cost-effectiveness and higher protein yield.

The wheat germ cell-free protein expression system segment is expected to grow lucratively over the forecast period. This system is a choice of preference for numerous applications in protein research comprising options for protein labeling and the expression of proteins such as multiple protein complexes and membrane proteins.

By application, the enzyme engineering segment held a larger share of the global market. Enzyme engineering plays an important role in bio manufacturing synthetic biology, and medicine.

The transcription & translation systems segment by method captured the highest revenue share of the market in 2021. Coupled transcription and translation (TNT) systems offer investigators time-saving options for eukaryotic in vitro transcription and translation, by connecting these processes in a single tube format.

By end-user, the pharmaceutical & biotechnological companies segment held a larger share in 2021, owing to the expansion of the current manufacturing capacities coupled with increasing prevalence of chronic disease which in turn demands for novel therapeutic drugs.

North America dominated the global market in 2021 due to the growth in the biotechnology and pharmaceutical industry, presence of high research and development investment, and the development of novel cell-free protein engineering products in the region.

The Asia Pacific is expected to grow considerably in the future increasing investments by major market players coupled with funding by the government for R&D.

A few of the key market players include Thermo Fisher Scientific, Inc,Takara Bio Company, New England Biolabs, Merck KGaA and others.

Read 160-page market research report, "Cell-free Protein Expression Market Size, Share & Trends Analysis Report By Product (Expression Systems, Reagents), By Application (Enzyme Engineering, Protein Labeling), By Method, By End-use, By Region And Segment Forecasts, 2022 - 2030", published by Grand View Research.

Cell-free Protein Expression Market Growth & Trends

Moreover, the surge in infectious diseases such as lower respiratory infections and human immunodeficiency virus (HIV), among others in recent years due to climate change, changing land-use patterns, and rapid urbanization are expected to aid in the market growth. For instance, according to WHO, lower respiratory infections ranked fourth place in causing deaths globally. In addition, in 2020, according to UNAIDS there were approximately 38.4 million people across the globe with HIV. Thus, the rise in infectious diseases require effective diagnosis and treatment options such as CFPE in the market. For instance, CFPE based system can be activated in less time by adding water. This feature helps in the portable diagnosis of infectious diseases. Therefore, rising infectious diseases can increase the applications of CFPS in treatment and diagnosis, and are likely to contribute to the market growth in the near future.

The development of vaccines and treatment was an emergency requirement globally to treat and combat the spread of COVID-19 infection. The low-cost, rapid manufacture and production of therapeutic antibodies were expected in the market. The conventional method of manufacturing antibodies relied on cell-based protein expression and this production required nine months or more. The CFPE-based vaccine production cut the time from a few months to one month or a few weeks. For instance, SwiftSacle Biologics, cell-free lysate-derived E. coli bacteria shrank the timeline of vaccine production from nine months to one month and turned out to be a game changer during the pandemic. Therefore, the CFPS advantages over traditional cell-based methods increased the applications of CFPS in the industries during COVID-19 and led to a boost in the market growth.

The increase in investments by various pharmaceuticals, biopharmaceutical companies is increasing the R&D activities of genomics & proteomics in drug development. For instance, Thermo Fisher Scientific invested in a spatial proteomics Ionpath firm to scale up the MIBIscope instruments and end-to-end spatial proteomics services to meet the increasing demand for services. In addition, in Jan 2022, Protai received funding of $8 million to provide an AI-based proteomics platform. This effective approach improved the development process and accuracy of drug discovery by saving time and lowering the costs of R&D. Such R&D investments increased the adoption of proteomics and genomics and are expected to contribute to the market growth.

On the other hand, Cell-free protein expression turns costly in the up scaled experiments due to the complexity of the cell-free lysates from the eukaryotic sources and the challenges in post-translational modifications of biomolecules due to misfolding or pleiotropic interactions with cellular components. The CFPE offers low protein production that can be used in small scale production and turns expensive for large scale production in industries. For instance, as per a research article published in the Journal of visualize experiments in Feb 2019, commercial CFPS kits, such as iPE-Quick Kit (Sigma-Aldrich) cost around USD 0.82 per microgram of protein, while Expressway (Thermo Fisher) costs about USD 0.76 per microgram of protein, excluding the cost of labor and equipment. Therefore, CFPE is expensive in large scale production and can impede the market growth.

Cell-free Protein Expression Market Segmentation

Grand View Research has segmented the global cell-free protein expression market based on product, application, method, end-use, and region:

Cell-free Protein Expression Market - Product Outlook (Revenue, USD Million, 2018 - 2030)

Expression Systems

E. coli Cell-free Protein Expression System

Wheat Germ Cell-free Protein Expression System

Rabbit Reticulocytes Cell-free Protein Expression System

Insect Cells Cell-free Protein Expression System

Human Cell-free Protein Expression System

Others

Reagents

Cell-free Protein Expression Market - Application Outlook (Revenue, USD Million, 2018 - 2030)

Cell-free Protein Expression Market - Method Outlook (Revenue, USD Million, 2018 - 2030)

Cell-free Protein Expression Market - End-User Outlook (Revenue, USD Million, 2018 - 2030)

Cell-free Protein Expression Market - Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

List of Key Players of Cell-free Protein Expression Market

Thermo Fisher Scientific, Inc.

Takara Bio Company

Merck KGaA

New England Biolabs

Promega Corporation

Jena Bioscience GmbH

GeneCopoeia, Inc.

Biotechrabbit GmbH

Cube Biotech GmbH

CellFree Sciences Co., Ltd.

Check out more related studies published by Grand View Research:

Cell Culture Protein Surface Coating Market - The global cell culture protein surface coating market size is expected to reach USD 2.5 billion by 2030, registering a CAGR of 15.2% from 2022 to 2030, according to a new report by Grand View Research, Inc. Increasing focus on stem cell research and development is the most crucial factor that drives the industry growth.

Protein Labeling Market - The global protein labeling market size is expected to reach USD 4.11 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.6% from 2022 to 2030. The study of Post-translational Modification (PTM) of proteins has gained immense popularity in cell biology and disease treatment and prevention.

Cell Line Development Market - Global cell line development market size is expected to reach USD 6.24 billion by 2022, according to a new report by Grand View Research, Inc. The Increasing demand for monoclonal antibodies and patent expiration of blockbuster biologics are expected to drive the cell line development industry over the forecast period.

Browse through Grand View Research's Biotechnology Industry Research Reports.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James Corporate Sales Specialist, USA Grand View Research, Inc. Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: sales@grandviewresearch.com Web: https://www.grandviewresearch.com Grand View Compass| Astra ESG Solutions Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg

Cision

View original content:https://www.prnewswire.com/news-releases/cell-free-protein-expression-market-to-be-worth-475-1-million-by-2030---grand-view-research-inc-301632900.html

SOURCE Grand View Research, Inc.

More here:
Cell-free Protein Expression Market to be Worth $475.1 Million by 2030 - Grand View Research, Inc. - Yahoo Finance

Insights on the Biobanks Global Market to 2027 – Regenerative Medicine Applications for Biobanking Market will Drive Growth – ResearchAndMarkets.com -…

DUBLIN--(BUSINESS WIRE)--The "Biobanks Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2017-2027 Segmented By Type, By Sample Type, By Application, By End User, By Region" report has been added to ResearchAndMarkets.com's offering.

The Global Biobanks Market stood at USD40.70 billion in 2021 and is expected to grow at an impressive rate of 8.22% during the forecast period. This can be ascribed to the growing investments and research & development in advanced therapies such as cancer genomic studies, personalized medicine, among others.

Biobanks play a pivotal role in disease diagnosis and development of a treatment or drug. The COVID-19 pandemic crisis has significantly increased the demand for biobanks worldwide. During the pandemic crisis various new specialized biobanks, focusing on COVID-19 were developed for research & development activities. For instance, in July 2021, Tulane University announced a new COVID-19 biobank containing blood & cell samples from survivors.

Regenerative Medicine Applications for Biobanking Market will drive the Market

Biobanks Market contributes to the advancement of biomedical and translational research by collecting and preserving biological samples such as blood, tissues, and nucleic acids, which are then made available for use in research to discover disease-relevant biomarkers; this information is then used for diagnosis, prognosis, and drug response prediction.

The increase in the number of research activities in this area is a major market driver. The availability of government financing for regenerative medicine, stem cell treatments, and cell and gene therapy are fueling this segment's research. Aside from that, the growing trend of cord blood banking will help this market segment develop. Future possibilities are predicted to include breakthroughs in orthopaedic therapies utilising stem cells.

Stakeholders Shifting Focus from Sample-driven to Data-driven Strategies

Precision medicine research is gaining traction as a result of the digital revolution. Precision medicine research and clinical data are also inextricably linked. Although there are times when there are modest connections between the two variables. Because the availability of data on well-characterized and high-quality samples is of relevance to healthcare organizations, this works as a profitable opportunity for stakeholders in the biobanking market.

Artificial intelligence (AI) and big data analytics are being introduced into the biobanking landscape in order to develop strong correlations between precision medicine research and clinical data. This has aided faster research, which has had a positive impact on the delivery of new pharmaceuticals in the healthcare industry. As a result, there is a growing demand in the biobanking industry for increased informatics capabilities.

Demand for Temperature Control Systems to Gain Strength in Biobanks Market

Biobanks are in high demand to preserve a variety of biospecimen, from blood to tissues, cells, and nucleic acids, due to the growing trend of personalized treatments to reduce chronic disease-related mortality rates.

As major manufacturers are focusing their efforts on the release of freezers and refrigerators, cryogenic storage systems, and other equipment for the storage of biobank samples, the market is expected to place a greater emphasis on temperature control systems, boosting global demand for Biobanks. The equipment segment is being driven by an increase in the number of Biobanks in several countries, as well as a desire for sophisticated biobanking equipment.

Companies Mentioned

Report Scope:

In this report, the Global Biobanks Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Biobanks Market, By Type:

Global Biobanks Market, By Sample Type

Global Biobanks Market, By Application:

Global Biobanks Market, By End-User:

Global Biobanks Market, By Region:

For more information about this report visit https://www.researchandmarkets.com/r/x26mlq

Read more from the original source:
Insights on the Biobanks Global Market to 2027 - Regenerative Medicine Applications for Biobanking Market will Drive Growth - ResearchAndMarkets.com -...

This breakthrough stem-cell therapy could reverse genetic blindness – Inverse

A promising method to treat blindness is to implant healthy light-sensitive cells into failing eyes. But these cell therapies which have been in development for at least three decades often fail because the implanted cells die rapidly or fail to incorporate themselves into the eyes. But new stem-cell research could potentially eliminate these roadblocks.

Whats new Experiments with human stem cells and dogs reveal that a cocktail of drugs that suppress the immune system could help implanted cells survive for months. In fact, the implanted cells even began integrating with the eyes, according to a new study published in the journal Stem Cell Reports.

The scientists injected immunosuppressed dogs with advanced stages of inherited retinal degeneration with the precursors to photoreceptor cells coaxed from human stem cells. They found that the immature cells developed into full-grown photoreceptors and that they started to form connections with the dogs neurons. The research offers a critical first step toward using stem-cell therapies to treat eye conditions, including inherited forms of blindness.

HERE'S THE BACKGROUND Genetic cases of blindness often result from problems with the light-sensitive rod and cone cells in the retina, the tissue that lines the inner eyeball. Scientists have had great success in treating some genetic eye conditions using gene therapies, which involve injecting working versions of malfunctioning genes into the eyes photoreceptor cells. But the genes responsible for many genetic cases of blindness remain unknown.

In turn, several forms of genetic blindness have no gene therapy or indeed any therapeutic options. And for some people it is already too late their condition has progressed so far that no photoreceptor cells remain intact, so gene therapy wouldnt have an effect anyway. Instead, regenerative therapies to replace ailing photoreceptors with functional cells could offer another avenue to reversing blindness.

How they did it In the new study, researchers dosed human stem cells with chemicals that coaxed them into forming the precursors of photoreceptor cells. To help track these cells positions over time, the stem cells were genetically modified to generate fluorescent proteins.

The scientists then injected them into the retinas of seven dogs with normal vision and three with advanced stages of inherited retinal degeneration. In the animals, these immature cells matured into photoreceptors.

When the stem cells were injected into the dogs with normal vision, their retinas were still intact, and therefore served as physical barriers that prevented the implanted cells from connecting with neurons in the eyes. But in the dogs with retinal degeneration (for which the treatment is targeted) the injected cells did a much better job migrating into the retina.

Since the canines immune systems would likely recognize the transplanted human cells as foreign entities and attack them, the researchers gave some immunosuppressive drugs.

As expected, injected cell numbers declined substantially in the canines who did not receive the drug cocktail, whereas cell numbers dipped but then kept steady in dogs who did receive the drugs. The cells in the immunosuppressed dogs survived up to five months post-injection. The researchers also detected signs of implanted cells connecting with neurons in the pups eyes.

Its challenging to turn stem cells into photoreceptors and ensure theyre fully integrated into the eye, but researchers hope patients own cells can eventually be used to treat blindness while avoiding adverse immune reactions.dra_schwartz/E+/Getty Images

Why it matters Discovering that human photoreceptor precursor cells could survive and mature into photoreceptor cells after being transplanted into an adult canine retina suggests regenerating a specific layer of the retina the one that contains rod and cone photoreceptors is possible in an adult eye.

This provides hope for being able to treat patients even in adulthood, Beltran says.

Importantly, the dogs used in this study also provide a better picture of how the same therapy might work in humans. Senior study author William Beltran, a veterinary ophthalmologist and vision scientist at the University of Pennsylvania, tells Inverse that dogs are good models for humans in this case for several reasons, ostensibly making translating the research into human bodies later a simpler task.

For one, large animal models with human-size eyes allow scientists to develop the same surgical approaches that may be used in people.

Dogs also receive therapy doses akin to those that would most likely be used in people, and they may experience some of the same immune reactions as we do.

WHAT'S NEXT In the future, the researchers will continue to refine their technique and eventually test whether the dogs experience improved vision due to the implanted cells.

Its still unclear why some implanted cells died within a few days following transplantation even when dogs were given immunosuppressive drugs. The team is investigating this process in hopes that they can try to improve graft survival, Beltran says.

All in all, future cell therapies for retinal degeneration may require immunosuppressive drugs if the donor cells arent genetically identical to the recipient. The best approach to prevent adverse immune reactions without using immunosuppressive drugs would be to inject stem-cell-derived photoreceptors from the patient after theyve been corrected for genetic defects, Beltran says.

Treatments for blindness may soon join the rapidly expanding and extremely expensive category of personalized medicine.

More like this

Some people with epilepsy find relief with CBD but the market is murky

By Kaiser Health News and Eric Berger

This genetically modified rice could transform the global food supply

By Joanna Thompson

This popular anti-aging goo can help regrow muscle study

By Miriam Fauzia

LEARN SOMETHING NEW EVERY DAY.

Original post:
This breakthrough stem-cell therapy could reverse genetic blindness - Inverse

Stem Cell Membrane-Coated Nanoparticles in Tumor Therapy – AZoNano

Cell membrane-coated nanoparticles, applied in targeted drug delivery strategies, combine the intrinsic advantages of synthetic nanoparticles and cell membranes. Although stem cell-based delivery systems were highlighted for their targeting capability in tumor therapy, inappropriate stem cells may promote tumor growth.

Study:Stem cell membrane-camouflaged targeted delivery system in tumor. Image Credit:pinkeyes/Shutterstock.com

A review published in the journalMaterials Today Biosummarized the role of stem cell membrane-camouflaged targeted delivery system in tumor therapy and focused on the underlying mechanisms of stem cell homing toward target tumors. Nanoparticle-coated stem cell membranes have enhanced targetability, biocompatibility, and drug loading capacity.

Furthermore, the clinical applications of induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs) were investigated as membrane-camouflaged targeted delivery systems for their anti-tumor therapies. In concurrence, the stem cell membrane-coated nanoparticles have immense prospects in tumor therapy.

Cell-based targeted delivery systems have low immunogenicity and toxicity, innate targeting capability, ability to integrate receptors, and long circulation time. Cells such as red blood cells, platelets, stem cells, tumor cells, immune cells, and even viral/bacterial cells can serve as effective natural vesicles.

MSCs derived from the umbilical cord (UC-MSCs), bone marrow (BM-MSCs), and adipose tissue (ATMSCs) are utilized in clinical applications. However, iPSCs are preferable over MSCs in clinical applications due to their easy fetch by transcription factor-based reprogramming of differentiation of somatic cells.

Stem cells (MSCs/ iPSCs) can be easily isolated and used as drug delivery systems for tumor therapy. Stem cell-based delivery systems have inflammation or tumor lesions targeting capacity. However, stem cells are often entrapped in the lung due to their size, resulting in microembolism.

Cell membrane-coated nanoparticles are applied in targeted delivery strategies. To this end, stem cell membrane-coated nanoparticles have tremendous prospects in biomedical applications. Although previous reports mentioned the role of cell membrane-coated nanocarriers in tumor therapy, delivery systems based on stem cell membranes have not been explored extensively.

Stem cell membrane-coated nanoparticles obtained from stem cells have complex functioning and can achieve biological interfacing. Consequently, stem cell membrane-coated nanoparticles served as novel drug delivery systems that could effectively target the tumor.

Previous reports mentioned the preparation of doxorubicin (DOX) loaded, poly (lactic-co-glycolic acid) (PLGA) coated MSC membrane-based nanovesicles, which showed higher cellular uptake than their PLGA uncoated counterparts. Similarly, the DOX-loaded MSC membrane-coated gelatin nanogels showed enhanced storage stability and sustained drug release.

Thus, the stem cell membrane-coated nanoparticles served as novel carriers for stem cells and facilitated the targeted delivery of the drugs at the tumor site. Since the stem cell membrane-coated nanoparticles had good targeting and penetration abilities, they enhanced the efficiency of chemotherapeutic agents in tumor therapy and minimized the side effects.

Reactive oxygen species (ROS) based photodynamic therapy (PDT) is mediated by photosensitizers with laser irradiations. Previous reports mentioned the development of MSC membrane-based mesoporous silica up-conversion ([emailprotected]2) nanoparticles that efficiently targeted the tumor due to their high affinity after being coated with MSC membrane.

These cell membrane-coated nanoparticles showed high cytocompatibility (with hepatocyte cells) and hemocompatibility (with blood). Moreover, the [emailprotected]2 nanoparticles-based PDT therapy under 980-nanometer laser irradiations could inhibit the tumors in vivo and in vitro. Consequently, the stem cell membrane-coated nanoparticles had circulation for an extended time and escaped the immune system, thereby increasing their accumulation at the tumor site.

Stem cell membrane-coated nanoparticles were also applied to deliver small interfering RNA (siRNA) via magnetic hyperthermia therapy and imaging. Previous reports mentioned the preparation of superparamagnetic iron oxide (SPIO) nanoparticles using an MSC membrane that reduced the immune response.

Additionally, the CD44 adhesion receptors were preserved on the surface of the MSC membrane during preparation. These prepared nanovesicles were unrecognized by macrophages, which enabled their stability in blood circulation. The nanosize and tumor homing capacity of MSCs helped the nanovesicles generate a dark contrast in T2-weight magnetic resonance imaging (MRI).

Cell membrane-coated nanoparticles helped fabricate various targeted delivery strategies. Especially, stem cell membrane-coated nanoparticles have the following advantages: stem cells are easy to isolate and expand in vitro. Thus, multilineage potential and phenotypes could be preserved for more than 50 population doublings in vitro.

Stem cell membrane-coated nanoparticles also have an intrinsic capacity to target inflammation or tumor lesions. Hence, these nanoparticles were established for tumor therapy, building a strong foundation for stem cell membrane-mediated delivery systems.

On the other hand, stem cell membrane-coated nanoparticles have the following drawbacks: Despite various sources for collecting MSCs (UC-MSCs/BM-MSCs/ATMSCs), the number of cells obtained is limited, although iPSCs are relatively easy to fetch by reprogramming differentiated somatic cells, the reprogramming is a high-cost step, restricting the clinical applications of iPSCs.

Zhang, W., Huang, X. (2022). Stem cell membrane-camouflaged targeted delivery system in tumor. Materials Today Bio.https://www.sciencedirect.com/science/article/pii/S2590006422001752

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

See the original post here:
Stem Cell Membrane-Coated Nanoparticles in Tumor Therapy - AZoNano